Pharmacokinetics of ADS-5102 (amantadine) Extended Release Capsules Administered Once-Daily at Bedtime for the Treatment of Dyskinesia

被引：0

作者：

Hauser, Robert ^{[1
]}

Pahwa, Rajesh ^{[2
]}

Wargin, William ^{[3
]}

Souza-Prien, Cindy ^{[4
]}

McClure, Natalie ^{[4
]}

Patni, Rajiv ^{[4
]}

Went, Gregory ^{[4
]}

机构：

[1] Univ South Florida, Tampa, FL USA

[2] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA

[3] Nuventra Pharma Serv Inc, Raleigh, NC USA

[4] Adamas Pharmaceut Inc, Emeryville, CA USA

来源：

NEUROLOGY | 2018年 / 90卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P2.043

引用

页数：2

共 50 条

[31] Among Parkinson's disease patients with both OFF and dyskinesia, ADS-5102 (amantadine) extended-release reduces disruptive motor episodes and improves function: Analysis of phase 3 trials
Hauser, R. A.
Chernick, D.
Formella, A.
MOVEMENT DISORDERS, 2020, 35 : S398 - S398
[32] Interim Results of an Ongoing Open-label Safety Study of ADS-5102 (amantadine hydrochloride) ExtendedRelease Capsules for Treatment of Levodopa-Induced Dyskinesia (LID) (EASE LID 2 Study)
Hauser, R.
Pahwa, R.
Tanner, C.
Oertel, W.
Isaacson, S.
Stempien, M. J.
Felt, L.
Johnson, R.
MOVEMENT DISORDERS, 2017, 32
[33] Effects of Once-Daily Opicapone 50 mg on the Pharmacokinetics of Levodopa Administered as Carbidopa/Levodopa Extended-Release Capsules: An Open-Label Phase 1 Study
Loewen, G.
Vijan, A.
Olson, K.
O'Reilly, T.
Liang, G.
Klepitskaya, O.
MOVEMENT DISORDERS, 2021, 36 : S219 - S220
[34] Effects of Once-Daily Opicapone 50 mg on the Pharmacokinetics of Levodopa Administered as Carbidopa/Levodopa Extended-Release Capsules: An Open-Label Phase 1 Study
Loewen, Gordon
Vijan, Arjun
Olson, Kurt
O'Reilly, Terry
Liang, Grace S.
Klepitskaya, Olga
ANNALS OF NEUROLOGY, 2021, 90 : S147 - S148
[35] Licarbazepine (LCBZ) Pharmacokinetics with Once-Daily Oxtellar XR® (Extended-release Oxcarbazepine)
Mendes, Shannon
Hur, Elizabeth E.
O'Neal, Welton
Sankar, Raman
NEUROLOGY, 2017, 88
[36] A comparison of the pharmacokinetics, clinical efficacy, and tolerability of once-daily tramadol tablets with normal release tramadol capsules
Bodalia, B
McDonald, CJ
Smith, KJ
O'Brien, C
Cousens, L
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2003, 25 (02) : 142 - 149
[37] Safety, tolerability, and pharmacokinetics of once-daily trazodone extended-release caplets in healthy subjects
Karhu, D.
Gossen, E. R.
Mostert, A.
Cronje, T.
Fradette, C.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2011, 49 (12) : 730 - 743
[38] Once-daily venlafaxine extended release (XR) vs. fluoxetine for the treatment of depression
Judge, R
JOURNAL OF AFFECTIVE DISORDERS, 2001, 66 (01) : 95 - 96
[39] Pharmacokinetics of a Once-Daily Extended-Release Formulation of Pramipexole in Healthy Male Volunteers: Three Studies
Jenner, Peter
Koenen-Bergmann, Michael
Schepers, Cornelia
Haertter, Sebastian
CLINICAL THERAPEUTICS, 2009, 31 (11) : 2698 - 2711
[40] Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease
Perez Lloret, Santiago
Rascol, Olivier
EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (13) : 2221 - 2230

← 1 2 3 4 5 →